Jennifer Dunlap

19PUBLICATIONS
126CO-AUTHORS
Gene and molecular therapyMolecular targetsHaematological tumoursMedical molecular engineering of nucleic acids and proteinsRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Jul 02, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

|Jun 02, 2026
Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors.

|Jun 01, 2026
Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.

|Mar 17, 2026
Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy for patients with myelofibrosis.

John O Mascarenhas, Laura Maria Fogliatto, Steven D Green

|Feb 03, 2026
Clinical outcomes of older patients with NPM1-mutated or KMT2A-rearranged AML before menin inhibitors: a Beat AML report.

Joshua F Zeidner, Jayanshu Jain, Rina Li Welkie

|Dec 04, 2025
Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors.

Aditi Chatterjee, Moaath K Mustafa Ali, Christopher M Bailey

Pageof 4

Frequent Collaborators

5 joint publications

Joshua F Zeidner

5 joint publications

Brian J Druker

4 joint publications

Curtis Lachowiez

4 joint publications

Alice S Mims